Clinical Trial Update: Evaluation of Tiotropium 2.5 and 5 µg Once Daily Delivered Via the Respimat Inhaler Compared to Placebo in Patient With Moderate to Severe Persistent Asthma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating tiotropium delivered by Respimat inhaler (2.5 and 5 mcg once daily) versus placebo in adults with moderate to severe persistent asthma;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Spiriva (tiotropium)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Asthma | Phase 3 | Status: COMPLETED | Results posted: 2014-07-04